These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11471759)

  • 41. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous immunoglobulin and multiple sclerosis.
    Achiron A; Miron S
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):247-54. PubMed ID: 16391400
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Escalating immunomodulatory therapy of multiple sclerosis. 1st supplement: December 2000].
    Multiple Sklerose-Therapie-Konsensus Gruppe (MSTKG)
    Nervenarzt; 2001 Feb; 72(2):150-7. PubMed ID: 11256151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multiple sclerosis and interferon beta-1b, past, present and future.
    Horowski R
    Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
    [No Abstract]   [Full Text] [Related]  

  • 45. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
    Gusev EI; Boĭko AN; Pozer Ch
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
    [No Abstract]   [Full Text] [Related]  

  • 46. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
    Galetta SL; Markowitz C; Lee AG
    Arch Intern Med; 2002 Oct; 162(19):2161-9. PubMed ID: 12390057
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate.
    Cadavid D; Cheriyan J; Skurnick J; Lincoln JA; Wolansky LJ; Cook SD
    J Neurol Neurosurg Psychiatry; 2009 Dec; 80(12):1337-43. PubMed ID: 19687024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current and investigational therapies used to alter the course of disease in multiple sclerosis.
    Miller A
    South Med J; 1997 Apr; 90(4):367-75. PubMed ID: 9114824
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Multiple sclerosis in children and adolescents: history and current experience of immunomodulating treatment].
    Bykova OV; Maslova OI; Guseva MR; Boĭko SIu; Totolian NA; Matveeva TA; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(4):4-10. PubMed ID: 15270293
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
    [No Abstract]   [Full Text] [Related]  

  • 53. Current developments in neurology, Part I: Advances in the pharmacotherapy of headache, epilepsy, and multiple sclerosis.
    Gidal BE; Wagner ML; Privitera MD; Dalmady-Israel C; Crismon ML; Fagan SC; Graves NM
    Ann Pharmacother; 1996 Nov; 30(11):1272-6. PubMed ID: 8913410
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis.
    Zang Y; Hong J; Robinson R; Li S; Rivera VM; Zhang JZ
    J Neuroimmunol; 2003 Apr; 137(1-2):144-53. PubMed ID: 12667659
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunomodulatory treatment of MS in Slovenia.
    Sega-Jazbec S
    Clin Neurol Neurosurg; 2002 Jul; 104(3):249-50. PubMed ID: 12127663
    [No Abstract]   [Full Text] [Related]  

  • 57. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.
    Yong VW
    Neurology; 2002 Sep; 59(6):802-8. PubMed ID: 12349849
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
    Goodin DS
    Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
    Dhib-Jalbut S
    Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients.
    Tilbery CP; Mendes MF; Oliveira BE; Thomaz RB; Kelian GR
    Arq Neuropsiquiatr; 2006 Mar; 64(1):51-4. PubMed ID: 16622553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.